Title: Jakking up tumor registry reporting of the myeloproliferative neoplasms
Abstract: American Journal of HematologyVolume 84, Issue 2 p. 124-126 LettersFree Access Jakking up tumor registry reporting of the myeloproliferative neoplasms H. Andrew Selinger, H. Andrew Selinger Prohealth Physicians Inc., Bristol, ConnecticutSearch for more papers by this authorXiaomei Ma, Xiaomei Ma Yale University School of Medicine, Department of Epidemiology and Public Health, New Haven, ConnecticutSearch for more papers by this author H. Andrew Selinger, H. Andrew Selinger Prohealth Physicians Inc., Bristol, ConnecticutSearch for more papers by this authorXiaomei Ma, Xiaomei Ma Yale University School of Medicine, Department of Epidemiology and Public Health, New Haven, ConnecticutSearch for more papers by this author First published: 10 November 2008 https://doi.org/10.1002/ajh.21333Citations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Rollison DE,Nadia H,Martyn TS, et al. List epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45–52. 10.1182/blood-2008-01-134858 CASPubMedWeb of Science®Google Scholar 2 Ma X,Vanasse G,Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008; 83: 359–362. 10.1002/ajh.21129 CASPubMedWeb of Science®Google Scholar 3 Lin CC,Lai MS,Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005; 104: 157–163. PubMedWeb of Science®Google Scholar 4 Tamblyn R,Lavoie G,Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999–1009. 10.1016/0895-4356(94)00234-H CASPubMedWeb of Science®Google Scholar 5 Berglund S,Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992; 48: 20–26. 10.1111/j.1600-0609.1992.tb01788.x CASPubMedWeb of Science®Google Scholar 6 Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Seminars in thrombosis and hemostasis. 2006; 32: 171–173. 10.1055/s-2006-939430 PubMedWeb of Science®Google Scholar 7 Bilgrami S,Greenberg BR. Polycythemia rubra vera. Semin Oncol 1995; 22: 307–326. PubMedWeb of Science®Google Scholar 8 Vardiman JW,Brunning RD,Harris NL. WHO histological classification of chronic myeloproliferative diseases. In: ES Jaffe, NL Harris, H Stein, JW Vardiman, editors. World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer (IARC) Press; 2001. pp 17–44. Google Scholar 9 Tefferi1 A,Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22. 10.1038/sj.leu.2404955 CASPubMedWeb of Science®Google Scholar 10 Ma X,Selinger A,Wang Y, et al. Incidence of polycythemia vera in the elderly. Blood 2007; 110 (ASH abstract). CASGoogle Scholar Citing Literature Volume84, Issue2February 2009Pages 124-126 ReferencesRelatedInformation